Rystiggo access in Lebanon: the MoPH-PDD named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Lebanon access Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive through the MoPH-PDD named-patient pathway, a the Pharmacy and Drug Department of the Lebanese Ministry of Public Health-administered mechanism that allows a Lebanese-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in USD.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

Why Lebanese patients need Rystiggo through the named-patient pathway

The Lebanese Republic operates a structured pharmaceutical regulatory environment. Rystiggo (rozanolixizumab-noli) is regulated through MoPH-PDD (the Pharmacy and Drug Department of the Lebanese Ministry of Public Health) channels, and a Lebanese family asking for Rystiggo is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.

Four converging patterns drive these cases. First, indication lag. Rystiggo's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash (fresh USD) payment, with limited NSSF (CNSS) coverage for chronic conditions and partial reimbursement under Bankers Assurance, MEDIS, and Allianz SNA private health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Lebanon or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.

In each pattern, the MoPH-PDD named-patient pathway is the mechanism that connects a Lebanese-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Rystiggo is a humanized IgG4 monoclonal antibody that blocks the neonatal Fc receptor (FcRn) to accelerate degradation of pathogenic IgG autoantibodies, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.

Current regulatory status of Rystiggo in Lebanon

Rystiggo (rozanolixizumab-noli; UCB) is a humanised IgG4 monoclonal antibody that blocks the neonatal Fc receptor (FcRn) to accelerate degradation of pathogenic IgG autoantibodies. The drug is FDA-approved in 2023 for generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine-receptor (AChR) or anti-muscle-specific-tyrosine-kinase (MuSK) antibody positive, administered as weekly subcutaneous infusion cycles of variable duration.

As of 2026-05-31, no public MOPH record of a Lebanon marketing authorisation for rozanolixizumab has been observed on the MOPH registered drugs list. UCB operates regionally through licensed distributors; a Lebanon registration timeline is not publicly documented.

Access for a Lebanese gMG patient proceeds through the MOPH Directorate of Pharmacy named-patient channel under Lebanese Pharmacy Profession Law No. 367/1994. The file specifies the autoantibody status (AChR or MuSK), the Myasthenia Gravis Activities of Daily Living (MG-ADL) baseline score, the Quantitative Myasthenia Gravis (QMG) score, prior therapy history (pyridostigmine, prednisone, mycophenolate, azathioprine, cyclosporine, methotrexate, IVIG, plasmapheresis, ravulizumab where applicable, eculizumab where applicable, efgartigimod where applicable), and the cycle plan (typical cycle: weekly subcutaneous infusion x 6 weeks per cycle, repeated based on clinical response).

Last verified by ARCH-74: 2026-05-31.

Named tertiary centres in Lebanon where Rystiggo is dispensed

Rozanolixizumab requires neurology specialty and a subcutaneous-infusion bay or trained patient-self-administration support. Lebanese centres equipped:

• American University of Beirut Medical Center (AUBMC), Beirut - Department of Neurology, neuromuscular sub-clinic; principal academic neuromuscular referral centre.
• Hotel-Dieu de France de Beyrouth (USJ), Beirut - Department of Neurology with neuromuscular sub-specialty.
• Saint George Hospital University Medical Center, Beirut - Department of Neurology.
• LAU Medical Center - Rizk Hospital, Beirut - Department of Neurology with infusion service.
• Rafik Hariri University Hospital, Beirut - public tertiary; Department of Neurology with limited neuromuscular sub-specialty experience.

The Lebanese Myasthenia Gravis patient community is small; cross-referral patterns concentrate at AUBMC neuromuscular clinic. Antibody testing (AChR, MuSK) is performed in-house at AUBMC and Hotel-Dieu, and via reference-laboratory send-out from smaller centres.

Local pricing reference for Rystiggo in Lebanon

US WAC reference for Rystiggo (rozanolixizumab, 280 mg/2 mL prefilled vial for subcutaneous infusion) is in the order of USD 65,000 to USD 85,000 per 6-week treatment cycle at the FDA-labelled weight-banded dosing (7 mg/kg per dose, once weekly x 6 weeks). The annual reference at multiple cycles is in the order of USD 350,000 to USD 500,000 depending on cycle frequency. Source: Rystiggo FDA Prescribing Information.

We quote Rystiggo in fresh USD throughout. No public LBP reference for rozanolixizumab has been observed on MOPH or hospital lists as of 2026-05-31.

Price snapshot date: 2026-05-31. Subcutaneous-infusion-bay charges, baseline immunoglobulin level monitoring, and infection-screen overhead are billed by the dispensing hospital separately.

Country-specific access barriers for Rystiggo in Lebanon

The principal barrier is funding. Post-2019 fiscal-crisis-related constraints have materially reduced the MOPH Pharmaceutical Aid Programme's capacity to fund novel high-cost neuro-immunology therapies. For a Lebanese gMG patient without private insurance, the dominant funding pattern is patient self-pay in fresh USD supplemented by UCB regional patient-access programmes where Lebanon is included.

Private-insurance coverage of FcRn-blocker therapy in Lebanon is policy-specific. Insurers including MEDGulf, Bankers Insurance, AROPE, Allianz SNA, AXA Middle East tightened specialty-drug coverage with USD-denominated pricing pressure during the crisis; pre-authorisation is uniformly required and approvals for novel mechanisms in chronic neuro-immune disease can be partial.

For Syrian and Palestinian refugee neurology patients UNHCR and UNRWA-supported pathways operate; rozanolixizumab has not customarily been UNHCR-supplied for chronic gMG management, although IVIG and plasmapheresis remain available through these routes. The clinical-justification file should anticipate questions about IVIG / plasmapheresis adequacy as comparator.

FcRn-blocker therapy requires baseline IgG-level documentation and ongoing monitoring (the mechanism reduces total IgG; infection vigilance is part of the care plan). The dispensing pharmacy file documents the baseline IgG and the monitoring schedule. Cold-chain (2 to 8 degree Celsius) is required for the prefilled vial; Beirut Rafic Hariri airport handles refrigerated pharmaceutical clearance routinely.

Recent local regulatory news touching Rystiggo or its drug class in Lebanon

No MOPH bulletin specifically naming rozanolixizumab or the FcRn-inhibitor / FcRn-blocker class (efgartigimod, rozanolixizumab, batoclimab in pipeline) has been observed in the last twelve months on the MOPH news and circulars page as of 2026-05-31. Adjacent context:

• FDA labelling and class-level safety signals on FcRn inhibitors (infection risk, headache, injection-site reactions) continue to be tracked. Source: FDA Drugs@FDA database.
• MOPH continues iterative Pharmaceutical Aid Programme communications under post-crisis fiscal constraints; specialty-drug-aid eligibility shifts have occurred several times. Source: MOPH.

What your physician needs to provide

For a Lebanese-licensed specialist prescribing Rystiggo through the MoPH-PDD pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Rystiggo is the appropriate next step given a humanized IgG4 monoclonal antibody that blocks the neonatal Fc receptor (FcRn) to accelerate degradation of pathogenic IgG autoantibodies.

The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Rystiggo (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.

The treating physician's Lebanese license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.

Common questions about Rystiggo in Lebanon

Will out-of-pocket cash (fresh USD) payment, with limited NSSF (CNSS) coverage for chronic conditions and partial reimbursement under Bankers Assurance, MEDIS, and Allianz SNA private health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Rystiggo is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by MoPH-PDD? The MoPH-PDD named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; MoPH-PDD review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Lebanese-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Lebanese Order of Physicians (Beirut or Tripoli branch) and the MoPH Pharmacy and Drug Department verifies the active license; the MoPH-PDD application records both the prescribing physician and the dispensing facility.

Can I receive Rystiggo at home? The dispensing facility must be Lebanese-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Where Reserve Meds fits in Rystiggo cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace MoPH-PDD, and we do not replace your dispensing pharmacy. For Rystiggo specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Lebanon, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Rystiggo case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the MoPH-PDD application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Lebanese tertiary specialty care concentrates at AUBMC, Hotel-Dieu de France, LAU Medical Center-Rizk Hospital, Clemenceau Medical Center, and Mount Lebanon Hospital in Beirut and Hazmieh; following the post-2019 currency crisis, specialty-medicine pricing is quoted predominantly in fresh US dollars, and the MoPH Pharmacy and Drug Department named-patient import authorisation is the standard mechanism for unregistered specialty medicines.

Next step

If your Lebanese physician has prescribed Rystiggo and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Reserved for you.

---

Related

• Rystiggo drug overview
• Lebanon country page
• Named-patient pathway overview